Advertisement
Screener

OUTLOOK THERAPEUTICS, INC. (OTLK) Investing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

OUTLOOK THERAPEUTICS, INC. Investing Cash Flow

OUTLOOK THERAPEUTICS, INC. (OTLK) reported Investing Cash Flow of -$2.10 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-18.

Financial Statements › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-18

  • OUTLOOK THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2020-09-30 was $0.00.
  • OUTLOOK THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2019-09-30 was -$1.00.
  • OUTLOOK THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2019-06-30 was -$150.74K.
  • OUTLOOK THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2019-03-31 was -$50.14K.
  • OUTLOOK THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2020 was -$900.00K.
  • OUTLOOK THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2019 was -$437.31K.
  • OUTLOOK THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2018 was -$2.78M.
  • OUTLOOK THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2017 was -$292.09K.
Period endNet Cash Provided by (Used in) Investing Activities 3 monthNet Cash Provided by (Used in) Investing Activities 6 monthNet Cash Provided by (Used in) Investing Activities 9 monthNet Cash Provided by (Used in) Investing Activities 12 month
2026-06-30-$2.10M
10-Q · filed 2026-08-18
2020-09-30$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-23
-$900.00K
10-K · filed 2021-12-23
2020-06-30-$900.00K
10-Q · filed 2021-08-13
2019-09-30-$1.00
derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-23
-$150.74K
derived: sum of 2 quarters · filed 2020-12-23
-$200.87K
derived: sum of 3 quarters · filed 2020-12-23
-$437.31K
10-K · filed 2020-12-23
2019-06-30-$150.74K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-14
-$200.87K
derived: sum of 2 quarters · filed 2020-08-14
-$437.31K
10-Q · filed 2020-08-14
-$1.70M
derived: sum of 4 quarters · filed 2020-08-14
2019-03-31-$50.14K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-15
-$286.57K
10-Q · filed 2020-05-15
-$1.55M
derived: sum of 3 quarters · filed 2020-05-15
-$1.72M
derived: sum of 4 quarters · filed 2020-05-15
2018-12-31-$236.43K
10-Q · filed 2020-02-14
-$1.50M
derived: sum of 2 quarters · filed 2020-02-14
-$1.67M
derived: sum of 3 quarters · filed 2020-02-14
-$1.94M
derived: sum of 4 quarters · filed 2020-02-14
2018-09-30-$1.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-19
-$1.43M
derived: sum of 2 quarters · filed 2019-12-19
-$1.71M
derived: sum of 3 quarters · filed 2019-12-19
-$2.78M
10-K · filed 2019-12-19
2018-06-30-$168.02K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-14
-$443.21K
derived: sum of 2 quarters · filed 2019-08-14
-$1.52M
10-Q · filed 2019-08-14
-$1.54M
derived: sum of 4 quarters · filed 2019-08-14
2018-03-31-$275.19K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-15
-$1.35M
10-Q · filed 2019-05-15
-$1.37M
derived: sum of 3 quarters · filed 2019-05-15
2017-12-31-$1.08M
10-Q · filed 2019-02-14
-$1.10M
derived: sum of 2 quarters · filed 2019-02-14
2017-09-30-$23.98K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-18
-$292.09K
10-K · filed 2018-12-18
2017-06-30-$268.11K
10-Q · filed 2018-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
Alpha Cognition Inc. (ACOG)$0.185B-6.77
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48